Here's your latest roundup of innovation news you may have missed. Photo via Getty Images

It's been a busy month so far with plenty of Houston startup news, major ecosystem events, and more — and there might be some headlines you may have missed.

In this roundup of short stories within Houston startups and tech, Solugen raises another mega round of funding, CorInnova snags a prestigious award, applications are open for two programs, and more.

Houston unicorn chemicals company raises $200M series D

Solugen closed its Series d funding round at $200 million. Photo via Getty Images

Houston-based Solugen has announced its latest round of investment to the tune of $200 million. The company, which reached unicorn status after its $357 million series C round last year, uses its patented Bioforge processes to produce "green" chemicals from bio-based feedstocks.

"Solugen is reimagining the chemistry of everyday life with enzymes found in nature. We make chemicals better, faster, cheaper, and without fossil fuels from right here in Houston, Texas. Whether you care about the climate, local competitiveness, or just plain old profits, we have good news: it's working," the company states in its news release.

"Our first Bioforge has been operating for a year and Solugen is running a nearly nine figure business with high margins selling commodity and specialty chemicals," the statement continues. "We have established ourselves with top tier customers for our existing solutions and fortune 100 technology partners to build a robust pipeline of future molecules that will help us achieve our goal of 10 mil tons of CO2 removed from the atmosphere."

According to the company, this latest raise has increased Solugen's valuation to over $2 billion. The round was led by investors Kennivik, Lowercarbon Capital, and Refactor Capital.

Houston health tech company wins funding from national organization

CorInnova has won a prestigious award. Photo via corinnova.com

Houston-based CorInnova was named one of five awardees from the National Capital Consortium for Pediatric Device Innovation's “Make Your Medical Device Pitch for Kids!” competition. Each honoree received a share of $150,000 in grant funding from the U.S. Food and Drug Administration. The awards ranged from $20,000 to $50,000 to support the advancement of pediatric medical devices.

CorInnova has designed a minimally invasive biventricular non-blood contacting cardiac assist device to treat heart failure.

The 2022 competition was moderated by California-based MedTech Innovator. The other four pediatric device innovation awardees included:

  • Innovation Lab, from La Palma, California, created a mechanical elbow brace stabilizes tremors for pediatric ataxic cerebral palsy to improve the performance of Activities of Daily Living.
  • Prapela, based in Biddeford, Maine, created the first innovation to improve the treatment of apnea of prematurity in over twenty years.
  • Tympanogen, from Richmond, Virginia, replaces surgical eardrum repair with a nonsurgical clinic procedure
  • Xpan, based in Concord, Ontario, has created a universal trocar enables safest and most dynamic access and effortless upsizing in conventional/mini/robotic procedures.

"We are delighted to recognize these five innovations with critical NCC-PDI funding that will support their journey to commercialization. Improving pediatric healthcare is not possible without forward-thinking companies that seek to address the most dire unmet needs in children’s health,” says Kolaleh Eskandanian, vice president and chief innovation officer at Children’s National Hospital and principal investigator of NCC-PDI, in a news release. "We know all too well how challenging it is to bring pediatric medical devices to market, which is why we have created this rich ecosystem to identify promising medical device technologies and incentivize investment. We congratulate this year’s winning innovators and applaud their efforts to help bridge these important care gaps that are impacting children.”

Houston real estate tech scores funding from Amazon entity

DOSS is a real estate tech company. Photo via Getty Images

Houston-based DOSS, which was chosen this summer for the inaugural Black Founders Build with Alexa cohort, has received funding from the Amazon Alexa Fund. The startups in the program were selected based on their ability to innovate with Alexa and build the next generation of voice, artificial intelligence, and ambient experiences technology.

DOSS is a digital brokerage that uses tech to make homeownership more affordable, and the company has developed a technology where customers are able to ask for real-estate advice and tips, search for home listings, get neighborhood information, and recent sales data, according to a news release from the company. They will also eventually be able to request to be connected with home service providers that serve their respective area.

CEO Bobby Bryant and COO Chris Norton founded DOSS in 2016. Last year, the company participated in the Google for Startups Black Founders program, receiving $100,000 from the fund.

TMC Innovation's Biodesign program applications open

Applications are open through the end of the year. Photo via tmc.edu

Applications are now open for the 2023 TMCi Biodesign program at the Texas Medical Center's Innovation Factory. TMC is looking for candidates with relevant backgrounds for starting a digital health or medical device company, such as: engineering, medicine, hospital administration, R&D (prototyping), software development, finance, legal, regulatory, reimbursement, or technical. Candidates must have at least 1 to 2 years of industry work experience or have prior startup history. It is preferred that applicants have earned an advanced degree.

The position is an in-person, full-time requirement that will begin August 2023 and will span nine months with an opportunity to extend for up to two months.

Applications close on December 31. Candidates will undergo a series of interviews in January and then will be extended offers in the spring.

HX Venture Fund calls for startups to meet visiting VC

Calling all Houston tech startups. Image via Screenshot

HX Venture Fund, a fund-of-funds that encourages and enables non Houston-based VCs to tap into the local innovation ecosystem, is hosting Creighton Hicks, partner at Austin-based LiveOak Venture Partners, later this month.

The organization is looking for Houston startups that are building a tech or tech-enabled services company raising a seed to series B round now or in the next six months. Startups have until November 18 to submit their interest via an online form.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.